Cholesterol Levels and Mortality: Defining the Optimal Ranges

Mengxi Du; Frank B. Hu

doi:10.1016/j.eng.2025.11.002

Engineering ›› :202511002 DOI: 10.1016/j.eng.2025.11.002

Views & Comments

research-article

Cholesterol Levels and Mortality: Defining the Optimal Ranges

Mengxi Du ^a
, Frank B. Hu ^a^,^b

Author information +

History +

PDF (589KB)

Cite this article

Download citation ▾

Mengxi Du, Frank B. Hu. Cholesterol Levels and Mortality: Defining the Optimal Ranges. Engineering 202511002 DOI:10.1016/j.eng.2025.11.002

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Jiang Q, Wu J, Yuan Y, Hao X, Long P, Liu K, et al. Low and decreasing cholesterol levels and risk of all-cause and cause-specific mortality: a prospective and longitudinal cohort study. Engineering. In press.

[2]	Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, et al. 2023 Chinese guideline for lipid management. Front Pharmacol 2023; 14:1190934.

[3]

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139: e1082-143.

[4]	He GD, Liu XC, Liu L, Yu YL, Chen CL, Huang JY, et al. A nonlinear association of total cholesterol with all-cause and cause-specific mortality. Nutr Metab 2021; 18:25.

[5]	Johannesen CDL, Langsted A, Mortensen MB, Nordestgaard BG. Association between low density lipoprotein and all cause and cause specific mortality in Denmark: prospective cohort study. BMJ 2020; 371:m4266.

[6]	Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis. JAMA Cardiol 2018; 3:823-8.

[7]	Chen Z, Wu P, Wang J, Chen P, Fang Z, Luo F. The association of statin therapy and cancer: a meta-analysis. Lipids Health Dis 2023; 22:192.

[8]	Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH. Statins, low-density lipoprotein cholesterol, and risk of cancer. Am Coll Cardiol J 2008; 52:1141-7.

[9]	Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. J Am Med Assoc 2006; 295:74-80.

[10]	Benn M, Tybjærg-Hansen A, Stender S, Frikke-Schmidt R, Nordestgaard BG. Low-density lipoprotein cholesterol and the risk of cancer: a Mendelian randomization study. J Natl Cancer Inst 2011; 103:508-19.

[11]	Carter P, Vithayathil M, Kar S, Potluri R, Mason AM, Larsson SC, et al. Predicting the effect of statins on cancer risk using genetic variants from a Mendelian randomization study in the UK Biobank. Elife 2020; 9:e57191.

[12]	Xiao M, Xu J, Wang W, Zhang B, Liu J, Li J, et al. Functional significance of cholesterol metabolism in cancer: from threat to treatment. Exp Mol Med 2023; 55:1982-95.

[13]	Huang B, Song B, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab 2020; 2:132-41.

[14]	Guligowska A, Stephenson SS, Cieślak-Skubel A, Kravchenko G, Korycka-Błoch R, Kostka TJ, et al. Low total cholesterol levels are associated with a high risk of malnutrition in older adults. Clin Nutr ESPEN 2023; 58:471.

[15]	Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001; 358:351-5.

[16]	Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG. Total cholesterol and risk of mortality in the oldest old. Lancet 1997; 350:1119-23.